S emaphorins are extracellular and membrane-associated proteins involved in many different cellular processes and are well known for their role in nervous system development through neuronal migration and axon guidance. 1 Semaphorin 3A (SEMA3A) was the first molecularly characterized neural chemorepellent, which when inactivated disrupts neural patterning and projections. 2 Although initial studies focused on SEMA3A's role in neurodevelopment, SEMA3A is also involved in cardiac innervation patterning. 3, 4 In This Issue, see p 411
first postnatal week, and electrocardiographic features of sinus bradycardia and mild ST-segment elevation, whereas transgenic SEMA3A-overexpressing mice have reduced sympathetic innervation, reduced I to density, prolonged action potential duration, spontaneous ventricular arrhythmias, and premature SCD. 3, 4 The patterning of murine SEMA3A is in a gradient, with greater expression in the endocardium and lesser expression in the epicardium. This differential gradient is opposite to the expression pattern gradient of the transient outward repolarizing current (epicardium>endocardium; I to , K v 4.3). 4 Interestingly, a portion of the SEMA3A protein is analogous to a tarantula toxin, hanatoxin. 6 Hanatoxin and closely related Heteropoda venatoria toxin (HpTx2) block K v 2.1 and K v 4.3 channels, respectively, by modifying energetics of activation via voltage sensor binding. 7, 8 Because of its sequence homology with toxins, we hypothesized that SEMA3A may act as a naturally occurring K v 4.3 (I to ) ion channel blocker, and the disruption of this interaction would lead to a pathological increase in I to current density.
Increase in I to current density is the pathogenic basis for a proportion of Brugada syndrome (BrS), a male-predominated disease often presenting in the fourth decade of life, characterized by cardiac conduction abnormalities, ST-segment elevation, and an increased risk for ventricular arrhythmias and SCD. [9] [10] [11] Sympathetic and parasympathetic patterning may also play an important role in the pathogenesis of BrS, 12 and arrhythmias in BrS are exacerbated by vagal stimulation. 13 Here, we demonstrate that SEMA3A is a naturally occurring protein inhibitor of K v 4.3 (I to ) channels and that SEMA3A is a possible BrS susceptibility gene.
Methods

Gene Constructs and Site-Directed Mutagenesis
SEMA3A complementary DNA in the pCR-BluntII-TOPO vector (Open Biosystems, Pittsburgh, PA) was subcloned into the pIRES2-dsRED2 vector (Clontech, Mountain View, CA). The pIreGFP plasmid encoding wild-type (WT) human K v 4.3 (KCND3) and green fluorescent protein represented I to current for electrophysiological studies. The K v 4.3-L274A and K v 4.3-V275A mutations were engineered into pIreGFP-KCND3-WT, and the SEMA3A-R552C and SEMA3A-R734W mutations were engineered into pIRES2-dsREDs-SEMA3A using primers containing each point mutation (available on request) in combination with the Quikchange XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA). Constructs for Na v 1.5, Ca v 1.2, and K v 4.2 are included in the Online Data Supplement. The integrity of all constructs was verified by DNA sequencing. For perfusion-based experiments, human SEMA3A protein (hSEMA3A; R&D Systems, Minneapolis, MN) was dissolved in PBS at a concentration of 1 mmol/L and diluted to work concentrations before experiments.
HEK293 Cell Culture and Transfection
HEK293 cells were cultured in minimum essential medium supplemented with 1% nonessential amino acid solution, 10% horse serum, 1% sodium pyruvate solution, and 1.4% penicillin/streptomycin solution. All cells were plated in T25 flasks and stored in a 5% CO 2 incubator at 37°C for 24 hours. Heterologous expression of K v 4.3 and SEMA3A was accomplished by cotransfecting 0.5 μg of pIreG-FP-KCND3 WT with 1.0 μg pIRES2-dsRed2-SEMA3A WT or pIRES2-dsRed2-SEMA3A R552C or pIRES2-dsRed2-SEMA3A R734W (0.5 μg of SEMA3A-WT plus 0.5 μg of mutant SEMA3A were used for heterozygote coexpression studies) using 5 μL of Lipofectamine transfection reagent (Invitrogen, Carlsbad, CA) in Gibco OPTI-MEM media (Invitrogen). Cells fluorescing 48 hours post-transfection were selected for electrophysiological experiments. HEK293 cell culture and transfection procedures for Na v 1.5, Ca v 1.2, and K v 4.2 are included in the Online Data Supplement.
Electrophysiological Measurements and Data Analysis for K v 4.3
Standard whole-cell patch clamp technique using an Axopatch 200B amplifier, Digidata 1440A, and pClamp version 10.2 software (Axon Instruments, Foster City, CA) was used to measure electrophysiological properties at room temperature (22-24 o C). The extracellular (bath) solution contained (mmol/L): 140 NaCl, 4 KCl, 2 CaCl 2 , 1 MgCl 2 , and 10 HEPES, pH adjusted to 7.4 with NaOH. The pipette solution contained (mmol/L): 110 KCl, 31 KOH, 10 EDTA, 5.17 CaCl 2 , 1.42 MgCl 2 , 4 MgATP, and 10 HEPES, pH adjusted to 7.2 with KOH following established protocols. 10, 14 Microelectrodes were pulled on a P-97 puller (Sutter Instruments, Novato, CA) and fire-polished to a final resistance of 2 to 3 MΩ. Series resistance was compensated by 80% to 85%. Currents were filtered at 5 kHz and digitized at 10 kHz. The voltage dependence of activation and inactivation was determined using voltage clamp protocols described in the figure legend. Data were analyzed using Clampfit (Axon Instruments), Excel (Microsoft, Redmond, WA), and fitted with Origin 8 (OriginLab Corporation, Northampton, MA).
Voltage-dependent inactivation curve was fitted with a Boltzmann function: I/I max ={1+exp[(V−V 1/2 )/k]} −1 , where V 1/2 and k are the halfmaximal voltage of inactivation and the slope factor, respectively. Inactivation time constants for each voltage step were determined by fitting a monoexponential function to current decay.
Electrophysiological measurements and data analysis for Na v 1.5, Ca v 1.2, and K v 4.2 are included in the Online Data Supplement.
K v 4.3 Total Cell and Cell Surface Western Blot Analysis
Cells were transfected in 25-cm 2 flasks using 4 μg lipofectamine mixed with 4 μg total plasmids (pBK-CMV encoding KCND3 with td-Tomato coexpressed with or without pBK-CMV encoding KChIP2 or pIRES2-dsRED2-SEMA3A). Plasmids were mixed in equal ratios and kept constant at 4 μg by the addition of empty (pBK-CMV) vector. Using previously described methods, 15, 16 Western blot analyses were performed on total protein lysates prepared from transfected HEK293 cells. The primary antibody was anti-K v 4.3 (UC Davis/NIH NeuroMab facility, Davis, CA). The mouse monoclonal anti-Transferrin receptor antibody (Invitrogen) was used as a loading control. The rabbit antimouse horseradish peroxidase-conjugated secondary antibody (Bethyl Laboratories, Montgomery, TX) followed by SuperSignal West Dura Extended Duration substrate (Pierce, Rockford, IL) was used for signal detection, captured using a Molecular Imager Chemidoc XRS system running Quantity One software version 4.6 (Bio-Rad Laboratories, Hercules, CA). The intensities of the K v 4.3 protein bands were determined using volume analysis from the Quantity One software and were normalized to Transferrin receptor in the same lane on the same blot. Results are expressed as means±SEM from 4 to 6 experiments.
Expanded protocols for the immunoblots of SEMA3A in mouse brain and human heart, as well as the coimmunoprecipitations of SEMA3A and K v 4.3, are available in the Online Data Supplement. Invitrogen) . At differentiation days 25 to 30, the enriched hiPSC-derived cardiomyocytes were subjected to enzymatic dissociation using 0.25% Trypsin/ EDTA plus 5% FBS to obtain single-cell suspensions of cardiomyocytes. These cells were added to 0.1% gelatin-coated glass coverslips maintained in B27/RPMI media and stored in a 5% CO 2 incubator at 37ºC before use. Standard whole-cell patch clamp technique, as described above, was used to measure I to currents in hiPSC-derived cardiomyocytes at room temperature (22-24ºC) . Currents were filtered at 1 kHz and digitized at 5 kHz. Data were analyzed as described above.
Cell Culture, Electrophysiological Measurements, and Data Analysis for Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Study Subjects and SEMA3A Mutational Analysis
Expanded methods regarding the BrS study subjects and SEMA3A mutational analysis are available in the Online Data Supplement.
Statistical Analysis
All data are expressed as mean±SEM. One-way ANOVA was performed to determine statistical significance among multiple groups, and paired t test was used to compare statistical significance before and after SEMA3A perfusion. P<0.05 was considered to be significant. Figure 1A shows the representative tracings of K v 4.3-WT, coexpression with SEMA3A-WT, and with paracrine expression of SEMA3A-WT in HEK293 cells. The paracrine expression of SEMA3A-WT represent cells themselves that are not expressing SEMA3A; however, they are in the same media as cells expressing SEMA3A (as confirmed by fluorescence). Analysis of the current-voltage relationship indicated that both SEMA3A-WT coexpression and paracrine expression significantly inhibited K v 4.3 current density from −20 to +40 mV (n=10 for each group; P<0.05 versus K v 4.3-WT; Figure 1B ). K v 4.3 peak current density at +40 mV (154.7±24.3 pA/pF; n=10) was significantly reduced by 66.3% with SEMA3A-WT coexpression (52.2±12.1 pA/pF; n=10; P<0.05) and 62.2% with paracrine expression of SEMA3A-WT (58.5±14.5 pA/pF; n=10; P<0.05), indicating that SEMA3A-WT is working on the extracellular surface to block K v 4.3 current. We also coexpressed K v 4.3 with KChIP2, a K v 4.3 chaperone, and SEMA3A had a similar marked inhibitory effect as described above (Online Figure I) . 
Results
K v 4.3 Current Inhibition by SEMA3A in Heterologous Expression System
SEMA3A's Inhibitory Effect on I to Is Independent of K v 4.3 Expression
To better understand how SEMA3A may be altering the properties of K v 4.3, we first examined the effects of SEMA3A on K v 4.3 protein expression. The overall loss of K v 4.3 current density when coexpressed with SEMA3A is independent of the expression levels of K v 4.3. Specifically, total cell and cell surface K v 4.3 expression is unaffected by SEMA3A in the presence and absence of KChIP2 ( Figure 1C-1F ).
SEMA3A Alters the Kinetic Properties of K v 4.3
Like SEMA3A coexpression, 100 nmol/L hSEMA3A protein perfusion significantly inhibited K v 4.3 current density from −10 to +40 mV (n=15; P<0.05 versus before hSEMA3A perfusion; Online Figure II ). To further determine if hSEMA3A protein could alter K v 4.3-WT current kinetics, we analyzed K v 4.3-WT inactivation time constants and steady-state inactivation parameters before and after perfusion with 100 nmol/L hSEMA3A. About 100 nmol/L hSEMA3A protein perfusion significantly decreased K v 4.3 decay time from 0 to 40 mV (n=15; P<0.05). At +40 mV, 100 nmol/L hSE-MA3A decreased inactivation time constant by 37.2% from 67.4±3.2 to 42.3±4.2 ms (n=15; P<0.05 versus before hSE-MA3A; Figure 2A ). Steady-state inactivation was assessed by a standard 2-pulse voltage clamp protocol ( Figure 2B ), and steady-state inactivation curves were fit using a Boltzmann function. 10 About 100 nmol/L hSEMA3A protein significantly shifted V 1/2 of inactivation from −38.9±1.5 mV (before hSE-MA3A; n=12) to −51.5±4.7 mV (after hSEMA3A; n=12; P<0.05; Figure 2B ). However, recovery from inactivation remained unchanged after perfusion of 100 nmol/L hSEMA3A (Online Figure III ).
SEMA3A Inhibits K v 4.3 Peak Current in a Dose-Dependent Manner
To explore whether hSEMA3A pharmacologically inhibits K v 4.3 current in a dose-dependent manner, K v 4.3-expressing cells were perfused with 0.1, 1, 10, and 100 nmol/L hSE-MA3A protein for 5 to 10 minutes. hSEMA3A protein dosedependently inhibited K v 4.3 current with an IC 50 of 4.4±1.3 nmol/L (n=5; Figure 2C and 2D).
SEMA3A's Inhibitory Effect on I to in Cardiomyocytes Derived From hiPSCs
To explore whether hSEMA3A protein also inhibits I to channels in human cardiomyocytes, we used control hiPSC-derived cardiomyocytes at differentiation days of 30 to 52 ( Figure 3A) , with average cell capacitance of 34.5±3.9 pF. First, we established that the captured currents elicit a notch in the action potential, which is expected for I to -mediated currents (Online Figure IV) . We then examined the effects of I to current density before and after 100 nmol/L hSEMA3A perfusion ( Figure 3B ), and the current-voltage relationship indicated that 100 nmol/L hSEMA3A protein significantly reduced I to current density across the voltage from +20 to +40 mV (n=5; P<0.05 versus before hSEMA3A perfusion; Figure 3C ). At +40 mV, I to peak current density was inhibited by 33.5% from 27.2±7.6 pA/pF (before hSEMA3A; n=5) to 18.1±5.3 pA/pF (after 100 nmol/L hSEMA3A; n=5; P<0.05; Figure 3D ).
SEMA3A May Be a K v 4.3 Channel-Specific Blocker
To determine the specificity of SEMA3A's effects, we incubated hSEMA3A with other cardiac ion channels related to BrS, including the sodium channel (SCN5A, I Na , Na v 1.5), the l-type calcium channel (CACNA1C, I Ca,L , Ca v 1.2), and the K v 4.3 highly homologous voltage-gated potassium channel, K v 4.2 (KCND2). B, Steady-state inactivation curves of K v 4.3-WT before and after 100 nmol/L hSEMA3A perfusion determined from a holding potential of −80 mV to prepulse of +20 mV in 5 mV increments with 0.5-s duration followed by a test pulse of +20 mV with 0.5-s duration and fitted with a Boltzmann function. 10 We found that Na v 1.5 ( Figure 4A and 4B) , Ca v 1.2 ( Figure 4C and 4D), and K v 4.2 ( Figure 4E and 4F) current densities were not measurably affected by SEMA3A, compared with SEMA3A's inhibitory effect on K v 4.3 with or without KCHIP2 coexpression.
Heart Expression of SEMA3A and Coimmunoprecipitation With K v 4.3
Because of the effects of SEMA3A on K v 4.3, we wanted to confirm whether SEMA3A is expressed in human cardiac tissue. As illustrated in Figure 5 , the polyclonal anti-SEMA3A antibody reliably detects native SEMA3A protein in (human) heart and (mouse) brain lysates. Western blot analysis of human ventricular lysates revealed robust expression of SEMA3A in the membrane fraction ( Figure 5A ). SEMA3A expression in adult mouse brain was particularly robust in the membrane fraction ( Figure 5B) ; therefore, to determine if there was a binding interaction between SEMA3A and K v 4.3, we did a coimmunoprecipitation in mouse brain tissue. We found that SEMA3A coimmunoprecipitates with K v 4.3 ( Figure 5C ). The coimmunoprecipitation of SEMA3A with the anti-K v 4.3 antibody was specific, as evidenced by the absence of signal in the control immunoprecipitation ( Figure 5C ). This data suggest a direct binding interaction between these 2 proteins.
SEMA3A's Inhibitory Effect on K v 4.3 Is Related to its Hanatoxin-Like Domain
A portion of SEMA3A's amino acid sequence is analogous to hanatoxin 6 ( Figure 6A ), which is closely related to HpTx2. HpTx2 selectively inhibits K v 4.3 through K v 4.3's voltage sensor, mediated by interactions with 2 K v 4.3 amino acids (L275 and V276, rat isoform). 8 Therefore, to determine whether SEMA3A may be binding to K v 4.3 in a similar location to HpTx2, we mutated the homologous amino acid residues in human K v 4.3, L274, and V275 to alanine. The L274A-K Figure V) , the overall effect of SEMA3A on peak current density is reduced for L274A. SEMA3A leads to a 38% reduction in K v 4.3-WT peak current density; however, SEMA3A leads to only an 18% reduction in L274A-K v 4.3 current density (P<0.05; Figure 6C ). SEMA3A has a larger effect on V275A-K v 4.3 peak current density, with a 29% reduction ( Figure 6C ).
Because the effects of SEMA3A are attenuated by L274A and V275A K v 4.3 substitutions, it may be possible that SEMA3A binds to the voltage sensor region on K v 4.3, and these mutations are disrupting this interaction.
SEMA3A Mutations May Contribute to the Pathogenesis of BrS
Overall, 4 SEMA3A missense mutations were identified in 10 patients (N153S, 2 cases; V435I, 6 cases; R552C, 1 case; R734W, 1 case) within our BrS cohort (Online Table I ). However, 2 missense mutations, R552C and R734W ( Figure 6A ), in 2 of 198 (1%) unrelated BrS patients (Table) , were absent in 500 European white controls, 300 Italian controls, 1094 subjects from the 1000 Genomes Project, 17 6503 subjects from the NHLBI GO Exome Sequencing Project, 18 and the 12000 Exome Chip 19 and were, therefore, considered as potentially pathogenic missense mutations and investigated functionally.
R552C-SEMA3A was identified in a 45-year-old man with a history of palpitations at rest. ST-segment elevation was observed in leads V1 and V2 on a Holter ECG, especially after large meals. Flecanide testing revealed a type 1 Brugada ECG pattern (Online Figure VIA and VIB) . Despite a reported negative family history of cardiac events, the patient's only living family member, a daughter, was clinically evaluated. She had a negative flecanide challenge and was R552C-SEMA3A mutation-negative.
R734W-SEMA3A was identified in an asymptomatic 44-year-old man with no family history. An ECG performed Figure 3 . Human SEMA3A (hSEMA3A) protein inhibited I to channel in humaninduced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). A, Representative hiPSC-CM cell for I to recording. B, Representative whole-cell I to traces before and after 100 nmol/L hSEMA3A protein perfusion elicited by step depolarization of 500 ms duration to +40 mV from a holding potential of −80 mV in 10 mV increments. C, Currentvoltage relationship for I to before and after 100 nmol/L hSEMA3A perfusion (n=5; *P<0.05 vs before hSEMA3A). D, Bar graph showing I to peak current density at +40 mV before and after 100 nmol/L hSEMA3A perfusion (n=5; *P<0.05 vs before hSEMA3A). All values represent mean±SEM.
for chest pain identified a type 2 Brugada ECG pattern, and a subsequent flecanide test induced a positive type 1 Brugada ECG pattern (Online Figure VIC and VID) . Ventricular fibrillation was noted during the diagnostic electrophysiology study, and an implantable cardioverter defibrillator was implanted subsequently. The patient's son had a negative flecanide test and was R734W-SEMA3A mutation-negative. Both R552C-and R734W-SEMA3A mutations when coexpressed with K v 4.3-WT resulted in an increased I to current density from −20 to +40 mV (R552C n=23; R734W n=20; P<0.05) compared with K v 4.3-WT plus SEMA3A (n=20; Figure 7A and 7B). SEMA3A mutant coexpression significantly increased K v 4.3 peak current density at +40 mV by 333.5% from 69.3±8.1 pA/pF (WT; n=20) to 300.4±55 pA/pF (R552C; n=23; P<0.05) and by 137.4% to 164.5±31.1 pA/pF (R734W; n=20; P<0.05; Figure 7C ). Additionally, R552C and R734W both significantly increased the I to total charge from −10 to +40 mV (P<0.05 versus K v 4.3-WT plus SEMA3A; Figure 7D ). However, neither SEMA3A mutations resulted in significant changes in decay time ( Figure 7E ) or steady-state inactivation ( Figure 7F ) when compared with K v 4.3 plus SEMA3A-WT coexpression.
In addition, electrophysiological analysis was completed in a heterozygous state, with K v 4.3-WT coexpression with SEMA3A-WT and SEMA3A-WT plus SEMA3A-R552C or SEMA3A-WT plus SEMA3A-R734W (Online Figure VII) . With these mutant SEMA3A-WT coexpressions, SEMA3A-WT plus SEMA3A-R552C still precipitated a marked increase in K v 4.3 current density from −30 to +40 mV (WT plus R552C n=15; P<0.05) compared with K v 4.3-WT plus SEMA3A-WT (n=15; Online Figure VIIC SEMA3A-R552C significantly increased K v 4.3 plus SEMA3A-WT peak current density at +40 mV by 220% from 70.9±10.6 pA/pF (SEMA3A-WT; n=15) to 226.9±44.5 pA/pF (SEMA3A-WT plus R552C; n=15; P<0.05; Online Figure VIID ). In contrast, SEMA3A-WT plus SEMA3A-R734W increased the K v 4.3 current density, by only 25.2% compared with SEMA3A-WT (peak current density 88.8±19.9 pA/pF; SEMA3A-WT plus R734W; n=14; Online Figure VIIC and VIID).
Discussion
SEMA3A Regulates I to Current Density and Kinetics
SEMA3A has robust expression in human heart tissue, and it has been established previously that K v 4.3 is expressed in the human heart. 20 In addition, SEMA3A transgenic mice have a reduction of I to density, reduced sympathetic innervation, and have the propensity for spontaneous ventricular arrhythmias. 3 In combination with our illustration of SEMA3A's effect on K v 4.3, this data suggest that SEMA3A not only regulates cardiac innervation patterning but may also regulate I to current densities to maintain a transmural repolarization gradient and prevent potentially lethal cardiac arrhythmias.
Here, we identified SEMA3A as a novel inhibitory regulator of K v 4.3 current density and kinetics because of direct binding of SEMA3A and K v 4.3 in a manner similar to toxin channel binding. SEMA3A has several similarities to toxins, which are known to physically bind and inhibit voltage-gated ion channels. SEMA3A has a 34-amino acid stretch analogous to hanatoxin, 6 which contains the 6 stereotypical cysteines ( Figure 6A ) of an inhibitor cystine knot motif commonly seen in invertebrate toxins. 21 This hanatoxin-like sequence in SEMA3A resides within a similar plexin/semaphorin/integrin domain in which the structure was described in SEMA4D (a close relative of SEMA3A).
Although the function of this domain is unknown, the plexin/ semaphorin/integrin domain folds using 3 disulfide bonds akin to the inhibitor cystine knot motif. 22 Therefore, SEMA3A has protein sequence characteristics of a toxin, which may support its ability to bind and inhibit ion channels.
Toxins are known to bind to the extracellular surface of ion channels. In our study, SEMA3A led to reduced current density of K v 4.3 in HEK293 cells whether coexpressed within the cell ( Figure 1A and 1B) , expressed in a paracrine fashion ( Figure 1A and 1B), or with hSEMA3A protein perfusion ( Figure 2 ). SEMA3A perfusion also reduced current density of I to in cardiomyocytes derived from hiPSCs (Figure 3 ). To establish a binding interaction, we were able to immunoprecipitate SEMA3A with an anti-K v 4.3 antibody in mouse brain ( Figure 5C ). Altogether, this data support the conclusion that SEMA3A is binding to K v 4.3, potentially at the extracellular surface, congruent with SEMA3A's previously established function as a naturally secreted protein binding to cell surface receptors. 2 In an attempt to determine where SEMA3A may be binding to K v 4.3, we focused on what has been previously established for toxin channel interaction. There are 2 major mechanisms in which toxins can interact with voltage-gated channels on the extracellular surface, through direct targeting of the ion channel pore or through binding to the channel's voltage sensor region, which influences the stability of closed, open, or inactivated states of the channel. 23 Hanatoxin and HpTx2 both fall into the latter category, binding to the voltage-sensing domain of K v 2.1 and K v 4.3, respectively. 7, 8 When bound, these toxins shift activation to more depolarized voltages, decrease current density, and rapidly inactivate channels, 23 all of which are seen when K v 4.3 is exposed to SEMA3A. The binding interaction between toxins and channels is regulated by the overall charge of the voltage sensor paddle region, and mutagenesis of this region can significantly alter the effects of the toxins. Similar to previous studies on K v 4.3 and HpTx2, 8 Inactivation time constants for each voltage step were determined by fitting a monoexponential function to current decay. F, Steady-state inactivation curves of K v 4.3-WT with SEMA3A-WT, SEMA3A-R552C, or SEMA3A-R734W determined from a holding potential of −80 mV to prepulse of +20 mV in 5 mV increments with 0.5-s duration followed by a test pulse of +20 mV with a 0.5-s duration fitted with a Boltzmann function. 10 All values shown represent mean±SEM.
channel, suggesting a direct interaction between SEMA3A and K v 4.3 voltage sensor.
SEMA3A: A Possible BrS Susceptibility Gene
The phenotype of murine SEMA3A knockout consisting of sinus bradycardia, decreased basal sympathetic activity, ST-segment elevation, and SCD prompted analysis of our BrS cohort. Here, we identified 2 ultrarare SEMA3A mutations, R552C and R734W, in 2 patients diagnosed with BrS. Interestingly, a common I334V-SEMA3A polymorphism was associated recently with a high incidence of unexplained cardiac arrest with ventricular fibrillation among pilsicainide challenge-negative Japanese individuals. 24 According to Nakano et al, 24 using the 1000 Genomes Project, 17 I334V has a prevalence of 2.1% in East Asians, 1.35% among West Africans, 1.86% among Americans, and 0% among Europeans. This mutation was not identified in our European white cohort. Functional characterization of this SEMA3A polymorphism identified a loss of function of axon collapse and led to disrupted innervation patterning in patient tissues. 24 Whether our SEMA3A mutation-positive BrS patients have an abnormal cardiac innervation pattern is currently unknown.
Coexpression of K v 4.3 with either SEMA3A mutation in a homozygous fashion led to a significant increase in I to current compared with K v 4.3 coexpressed with SEMA3A-WT. We speculate that each mutation may cause misfolding of SEMA3A, thereby either disrupting the hanatoxin-like sequence altering SEMA3A-K v 4.3 binding or preventing SEMA3A secretion. These effects would presumably disrupt SEMA3A's normal suppressive effect on K v 4.3, therefore leading to an increase in I to current. Interestingly, R552C is 3 amino acids away from the SEMA3A hanatoxin-like sequence. This region, within the plexin/semaphorin/integrin domain, is known to fold with 3 disulfide bonds between 6 cysteine residues ( Figure 6A ). The addition of a new cysteine as a result of the R552C mutant could lead to the formation of a novel disulfide bond, thus altering the folding structure of the plexin/semaphorin/integrin domain, directly affecting this toxin-like region, which in turn could alter binding to K v 4.3. In addition, the R734W mutation within the basic SEMA3A C-terminus substitutes a basic amino acid, arginine, to a hydrophobic uncharged amino acid, tryptophan, which could affect the overall charge of this region and alter its folding structure.
After heterozygote coexpression of mutant and SEMA3A-WT together, R734W no longer accentuates K v 4.3 current density significantly, at least in a HEK293 cell model system during WT plus mutant coexpression studies that attempt to mimic the heterozygous state. However, without examination of protein expression in our patient, we do not know if these 50:50 studies are truly reflective of human expression. The mutations themselves could alter the expressivity of the mutant SEMA3A, potentially leading to a more robust phenotype. In addition, growth cone collapse assays for each of the mutants have not been completed. Therefore, it is possible that either of these mutations could still contribute to a BrS-like phenotype, in a nerve growth-related manner. These SEMA3A mutants could also alter the normal expression patterning of SEMA3A, disrupting the known SEMA3A and K v 4.3 expression gradients. Additional experimentation in the form of transgenic mice may help elucidate some of the potential developmental innervation changes, which may develop because of mutations within SEMA3A.
Altogether, based on our electrophysiological studies, we know that a rare R552C-SEMA3A mutation attenuates SEMA3A's ability to block K v 4.3, resulting in a substantial accentuation of K v 4.3 current. Previously, we have demonstrated that primary mutations in KCND3-encoded K v 4.3 cause BrS through a marked gain of K v 4.3 current. 10 Accordingly, in a final common pathway fashion, it is possible that the SEMA3A perturbation underlies their disease. However, because the cases in which these mutations have been identified do not have sufficient pedigree information to test cosegregation, we cannot be certain that the SEMA3A mutation is solely responsible for BrS in these 2 patients.
Potential for SEMA3A as a Therapeutic I to -Specific Channel Blocker
Gain of function in I to underlies a subset of BrS being first identified in patients with BrS harboring mutations in KCNE3. 25 Subsequently, we identified 2 mutations within KCND3-encoded K v 4.3 in patients with BrS. 10 Mutations in each of these genes caused a significant gain of function in I to current. One of the current treatment strategies for patients with BrS is quinidine, which blocks a variety of channels. However, quinidine's I to blocking activity may underlie its therapeutic efficacy in patients with BrS, regardless of the primary pathogenic substrate. [26] [27] [28] In principle, an I to -specific blocker might be more effective than quinidine in managing patients with symptomatic BrS. This study provides evidence that SEMA3A may have a potential as a novel therapeutic as an I to -specific blocker. First, SEMA3A has drug-like properties, with a dose-dependent response curve as shown in Figure 2C and 2D. Second, SEMA3A does not alter the current density of other inward cardiac ion channels, such as Na v 1.5 or Ca v 1.2, or another fast transient outward current potassium channel, K v 4.2 (Figure 4 ), lending support that SEMA3A may be a channel-specific blocker for K v 4.3. Many of the known K v 4.3 blockers also block other potassium channels or inward currents. 26 Therefore, SEMA3A, or a synthetically derived toxin-like portion of SEMA3A, could potentially be developed into a treatment strategy for patients with symptomatic BrS.
Conclusions
We have identified a novel function for SEMA3A as a potential K v 4.3-specific channel blocker. In addition, with the identification of rare functionally significant mutations, perturbations in SEMA3A may contribute to BrS. The identified effects of SEMA3A on K v 4.3 may be because of a direct binding interaction in a mechanism similar to toxin channel binding, and these findings might stimulate the development of a novel I to -specific channel blocker for therapeutic intent.
